Skip to main content
SpringerLink
Log in

Ixekizumab versus secukinumab for PsA in the UK

  • Unknown
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Funded by Eli Lilly and Company.

Reference

  • Schweikert B, et al. Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. Internet Document : 12 Mar 2020. Available from: URL: https://doi.org/10.1007/s41669-020-00202-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ixekizumab versus secukinumab for PsA in the UK. PharmacoEcon Outcomes News 849, 17 (2020). https://doi.org/10.1007/s40274-020-6668-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6668-x

Search

Navigation